Topical Insights Into the Post-Approval Controversies of Aducanumab

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhiraj Kumar, Dharmendra Kumar Yadav, Md Imtaiyaz Hassan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Alzheimer’s drug Aducanumab Neurodegenerative diseases FDA—Food and drug administration Neuropsychological Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e5a0627f956e42a49988b473d2b2ea66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5a0627f956e42a49988b473d2b2ea66
record_format	dspace
spelling	oai:doaj.org-article:e5a0627f956e42a49988b473d2b2ea662021-11-18T07:20:06ZTopical Insights Into the Post-Approval Controversies of Aducanumab1663-981210.3389/fphar.2021.787303https://doaj.org/article/e5a0627f956e42a49988b473d2b2ea662021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.787303/fullhttps://doaj.org/toc/1663-9812Dhiraj KumarDharmendra Kumar YadavMd Imtaiyaz HassanFrontiers Media S.A.articleAlzheimer’s drugAducanumabNeurodegenerative diseasesFDA—Food and drug administrationNeuropsychologicalTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer’s drug Aducanumab Neurodegenerative diseases FDA—Food and drug administration Neuropsychological Therapeutics. Pharmacology RM1-950
spellingShingle	Alzheimer’s drug Aducanumab Neurodegenerative diseases FDA—Food and drug administration Neuropsychological Therapeutics. Pharmacology RM1-950 Dhiraj Kumar Dharmendra Kumar Yadav Md Imtaiyaz Hassan Topical Insights Into the Post-Approval Controversies of Aducanumab
format	article
author	Dhiraj Kumar Dharmendra Kumar Yadav Md Imtaiyaz Hassan
author_facet	Dhiraj Kumar Dharmendra Kumar Yadav Md Imtaiyaz Hassan
author_sort	Dhiraj Kumar
title	Topical Insights Into the Post-Approval Controversies of Aducanumab
title_short	Topical Insights Into the Post-Approval Controversies of Aducanumab
title_full	Topical Insights Into the Post-Approval Controversies of Aducanumab
title_fullStr	Topical Insights Into the Post-Approval Controversies of Aducanumab
title_full_unstemmed	Topical Insights Into the Post-Approval Controversies of Aducanumab
title_sort	topical insights into the post-approval controversies of aducanumab
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/e5a0627f956e42a49988b473d2b2ea66
work_keys_str_mv	AT dhirajkumar topicalinsightsintothepostapprovalcontroversiesofaducanumab AT dharmendrakumaryadav topicalinsightsintothepostapprovalcontroversiesofaducanumab AT mdimtaiyazhassan topicalinsightsintothepostapprovalcontroversiesofaducanumab
_version_	1718423633781587968

Topical Insights Into the Post-Approval Controversies of Aducanumab

Ejemplares similares